The use of immunosuppressive and combination treatments for interstitial lung disease associated with systemic sclerosis (SSc-ILD) has increased significantly over the past two decades, with more than half of patients now starting treatment at their first evaluation, according to a new study. Over the same period, rates of…
Levels of soluble CD13, the circulating form of a protein involved in inflammation and fibrosis (scarring), are generally higher in people with scleroderma, but do not clearly correlate with disease severity or specific clinical features, a new study reports. The findings suggest that CD13 alone is unlikely to serve…
Mesenchymal stem cells (MSCs) — a type of regulatory cell found in various tissues — work to reduce lung scarring in systemic sclerosis (SSc) by suppressing the growth of certain immune T-cells that carry the PD-1 receptor, according to a new study. PD-1 is an immune checkpoint protein…
Becoming educated and informed about scleroderma is a good first step. Here you’ll find general information about the disease, including diagnosis, symptoms, and causes.
It helps to know others have been where you are now. Here’s a collection of our columnists’ words of wisdom to help you along on your scleroderma journey.
There is no cure for scleroderma yet, but here you can find more information about current therapeutic approaches, as well as experimental treatments that are in the pipeline.
Get regular updates to your inbox.
